The in vitro cytotoxicity and genotoxicity of cigarette smoke particulate matter with reduced toxicant yields  by Combes, R. et al.
Toxicology in Vitro 27 (2013) 1533–1541Contents lists available at SciVerse ScienceDirect
Toxicology in Vitro
journal homepage: www.elsevier .com/locate / toxinvi tThe in vitro cytotoxicity and genotoxicity of cigarette smoke particulate matter
with reduced toxicant yields
R. Combes ⇑,1, K. Scott, I. Crooks, D. Dillon, C. Meredith, K. McAdam, C. Proctor
British American Tobacco, Group Research and Development, Regents Park Road, Southampton SO15 8TL, UK
a r t i c l e i n f oArticle history:
Received 26 October 2012
Accepted 12 March 2013
Available online 27 March 2013
Keywords:
Genotoxicity
Cytotoxicity
In vitro
Tobacco smoke
Particulate matter
Tobacco sheet substitute
Blend-treated tobacco
Toxicant0887-2333 2013 Elsevier Ltd.
http://dx.doi.org/10.1016/j.tiv.2013.03.005
⇑ Corresponding author. Tel.: +44 7968709236.
E-mail address: robert.d.combes@gmail.com (R. Co
1 Independent Consultant, Norwich, UK
Open access under CC BY-Na b s t r a c t
Tobacco smoke contains more than 5600 constituents, of which approximately 150 are toxicants. This
paper describes the activities in the Neutral Red uptake (NRU) assay, the Salmonella mutagenicity test
(SAL), the mouse lymphoma mammalian cell mutation assay (MLA) and the in vitro micronucleus test
(IVMNT) of Particulate Matter (PM) obtained from experimental cigarettes (ECs), designed to produce
reduced levels of toxicants. The designs included tobacco substitute sheet (TSS) containing glycerol,
which dilutes toxicants in smoke, or the incorporation of blend-treated (BT) tobacco to reduce the levels
of nitrogenous toxicant precursors and some polyphenols. All samples were cytotoxic in the NRU, how-
ever TSS reduced PM cytotoxicity in this assay. All PMs were mutagenic in the SAL, MLA and IVMNT.
Reductions in bacterial mutagenicity were observed in the SAL, for cigarettes with BT tobacco, compared
with their respective controls. The quantitative changes in bacterial mutagenicity could be explained by
analytical chemistry data on smoke generated from the ECs used in the study. These observations, and the
absence of consistent qualitative differences in the activities of the experimental, control and reference
cigarettes, suggest that reduced toxicity cigarettes, as measured by the tests described in this paper,
may be developed without introducing any additional cytotoxic or genotoxic hazards, but the impact
of this on human health risks remains unknown.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction ganic content of the TSS and hence smoke yields. The glycerol (ca.Tobacco smoke is a complex, dynamic, mixture of more than
5600 identiﬁed constituents (Perfetti and Rodgman, 2011), of
which approximately 150 have been documented as toxicants
(Fowles and Dybing, 2003).
In recent papers we have described four different individual
technological approaches to the reduction of toxicants in cigarette
smoke, two of which modiﬁed the tobacco blend (McAdam et al.,
2011; Liu et al., 2011), and two of which modiﬁed the cigarette ﬁl-
ter (Branton et al., 2011a, 2011b).
This paper describes an assessment of the in vitro toxicities of
experimental cigarettes (ECs) incorporating these technologies.
The designs include the use of tobacco substitute sheet (TSS), which
has the dual function afforded by containing glycerol to dilute toxi-
cants in smoke, and by the provision of a low organic content mate-
rial in order to reduce the amount of tobacco burnt in the cigarette,
and hence smoke yields. Another cigarette includes blend-treated
(BT) tobacco to reduce the levels of toxicant precursors in tobacco
and hence of toxicants in the tobacco smoke generated from them.
TSS is a new material, which, in addition to high levels of glyc-
erol, also contains calcium carbonate (ca. 75%) to minimise the or-mbes).
C-ND license.12%) distils into the smoke to dilute the tar, by contributing to the
total amount of particulate smoke, measured as nicotine-free dry
particulate matter (NFDPM) (also known as ‘tar’). As most ciga-
rettes are designed to meet a speciﬁc International Standards Orga-
nisation (ISO) NFDPM yield value, incorporation of glycerol into the
smoke stream effectively results in a reduced contribution of the
tobacco combustion products to the overall NFDPM value, a pro-
cess termed ‘dilution’. Conﬁrmation of the dilution effect through
the incorporation of TSS into cigarettes, has been achieved by
showing reductions in a wide range of smoke constituents, after
smoking TSS containing cigarettes (McAdam et al., 2011).
Cigarettes with BT tobacco have also been developed. BT tobac-
co has reduced levels of soluble and insoluble proteins, and amino
acids in tobacco, which act as toxicant precursors, as well as re-
duced levels of water soluble polyphenols, such as chlorogenic
acid, rutin and scopoletin. The BT process is based on the fact that
proteins and amino acids have been reported to be precursors for a
number of potentially toxic constituents of tobacco smoke, includ-
ing 2-aminonaphthalene and 4-aminobiphenyl (Torikaiu et al.,
2005) and mutagenic heterocyclic amines (Mizusaki et al., 1977;
Matsumoto and Yoshida, 1981; Clapp et al., 1999), the latter being
implicated as a primary source of genotoxicity of cigarette smoke
condensates (CSCs) (DeMarini, 2004).
The BT process is carried out on cut, ﬂue-cured tobacco, and
involves the sequential extraction of the tobacco with water,
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with an aqueous protease enzyme solution, and by further treat-
ment of the resulting solution with adsorbents, followed by reap-
plication of the remaining soluble materials to the extracted
tobacco. The treated tobacco retains the structure of the original
tobacco, and is designed to be used with an adsorbent ﬁlter, to cre-
ate a cigarette with a conventional appearance, usage, and smoking
experience (Liu et al., 2011).
Most cigarette ﬁlters contain cellulose acetate, however, adsor-
bant ﬁlters were developed containing CR20L ion-exchange resin.
CR20L is an amine-functionalised resin bead material which can
be incorporated into cigarette ﬁlters (Diainon, Mitsubishi Chemical
Corporation, Tokyo). The characterisation and use of CR20L in cig-
arette ﬁlters were described in detail by Branton et al. (2011b). In
comparison to ﬁlters containing conventional activated carbon,
CR20L offers superior reductions for hydrogen cyanide (HCN),
formaldehyde and acetaldehyde.
Activated carbon is more efﬁcient than CR20L in removing other
volatile constituents from the smoke stream. One of the ﬁlters in
the study contained a polymer-derived activated carbon, with a
modiﬁed pore structure, to increase adsorption of a range of vola-
tile smoke constituents (Branton et al., 2009). Two of the ﬁlters
contained both CR20L and polymer-derived activated carbon.
Full details of the design and performance of these experimen-
tal cigarettes are described elsewhere (McAdam et al., 2012).
The results are described of subjecting cigarette smoke particu-
late matter (PM) samples, generated under ISO machine-smoking
conditions (ISO 3308:1977) from reference, control and reduced
toxicant cigarettes, to four in vitro toxicity assays. These assays –
Neutral Red uptake (NRU), Salmonella mutagenicity test (SAL),
the mouse lymphoma mammalian cell mutation assay (MLA) and
in vitro micronucleus test (IVMNT) – have been accepted by regu-
latory agencies and the Organisation of Economic Cooperation and
Development (OECD) (Aardema et al., 2006; Anon, 2006; Corvi
et al., 2008; Honma et al., 1999a; Garriott et al., 2002; Kirsch-Vol-
ders et al., 2003; Matsushima et al., 1999; Phelps et al., 2002). The
methods were also recommended by the Cooperation Centre for
Scientiﬁc Research Relative to Tobacco (CORESTA) (Anon, 2010).2. Materials and methods
2.1. Cigarettes
Cigarette speciﬁcations are detailed in Table 1. 3R4F and M4A
were reference cigarettes, providing historical control data. CC1
and CC6 were the control cigarettes, with ISO tar yields of 1 mg
and 6 mg per cigarette respectively (ISO, 2000). CC1 and CC6 con-Table 1
Composition of different cigarettes smoked to yield PM test products.
PM/cigarette code Blend Filter
CC6 United States (US)-style blend Cellulose acet
TSS6 US-style blend (80%)a/TSSb (20%) Two stage ﬁlt
CC1 US-style blend Cellulose acet
TSS1 US-style blend (80%)a/TSSb (20%) Three stage ﬁ
BT1 US-style blenda (25%)/BT tobaccof (75%) Three stage ﬁ
M4Ag Flue-cured blend Cellulose acet
3R4Fh US-style blend Cellulose acet
a Leaf tobacco.
b Tobacco substitute sheet.
c Cellulose acetate as found in conventional cigarettes.
d Polymer-derived activated carbon to adsorb a broad range of volatile components.
e Ion exchange resin ﬁlter additive to selectively adsorb volatile acidic and carbonyl s
f Tobacco treated to remove some of the protein and phenols by the method describe
g M4A is the historical reference cigarette used by British American Tobacco (BAT).
h 3R4F reference cigarettes used to provide historical control data (originally obtainedtained conventional cigarette materials. TSS6, TSS1 and BT1 were
the test cigarettes, to evaluate the new materials. CC1 was the con-
trol for TSS1 and BT1. CC6 was the control for TSS6.2.2. PMs
Tobacco preparation, cigarette manufacture and PM production
were undertaken at BAT Group Research and Development, South-
ampton, United Kingdom (UK). To generate cigarette smoke PM,
cigarettes were conditioned according to the ISO method, for a
minimum of 48 h at 22 ± 1 C and 60 ± 3% relative humidity (ISO,
1999) and smoked on a RM20CSR smoking machine (Borgwalt-
KC, Hamburg, Germany) using ISO standard pufﬁng parameters
(35 ml puff volume taken over 2 s once per minute) (ISO, 2000).
An appropriate number of cigarettes were smoked to obtain
approximately 220 mg PM on a 44 mm Cambridge ﬁlter pad
(Whatman, Maidstone, UK). The pads were weighed before and
after smoking to determine the weight of particulate matter depos-
ited, and the PM was then eluted in dimethyl sulphoxide (DMSO)
to a concentration of 24 mg/ml and stored protected from light
in single-use aliquots at 80 C.
Samples were shipped at 80 C to an independent laboratory
for in vitro tests, where they were stored at 80 C, and used with-
in 1 month. Crooks et al., 2013 have demonstrated stability of PM
when stored at 80 C for up to 2 years.
Test material was tested at different concentrations calculated
as lg/ml of PM. At the end of scoring, the concentration data were
corrected to give the NFDPM concentration. This was achieved by
gas chromatographic analysis of PM from each smoke run to deter-
mine nicotine and water contents. The resulting information was
used to compute an NFDPM correction factor to convert the con-
centration of PM tested to NFDPM in lg/ml for each test material.
The correction factor was applied to the experimental data to con-
vert the test concentrations from lg PM/ml to lg NFDPM/ml, by
using the formula:
NFDPM concentration ¼ ðPM dose NFDPM factorÞ
NFDPM concentrations were used to compare the toxicities of
the different PMs.2.3. In vitro toxicology testing
All in vitro tests were performed in an independent GLP labora-
tory. Aroclor 1254 induced rat liver post-mitochondrial superna-
tant (S9) mix provided metabolic activation in the genotoxicity
assays.atec
er of cellulose acetatec/modiﬁed charcoald (80 mg)
atec
lter of cellulose acetatec/modiﬁed charcoald (60 mg)/CR20L (20 mg)e
lter of cellulose acetatec/cavity with modiﬁed charcoald (60 mg)/CR20L (20 mg)e
atec
atec
moke constituents.
d.
from the University of Kentucky).
Table 2
Responses of PMs in the Neutral Red Uptake Assay (two experiments).
PM Experiment 1 Experiment 2
IC50 (lg NFDPM/ml) Variancea IC50 (lg NFDPM/ml) Variancea
3R4F 46.54 2.11 51.64 1.46
M4A 36.91 0.82 48.11 0.41
CC6 40.07 1.23 43.65 0.43
TSS6 50.19 1.28 47.28 1.34
CC1 28.18 2.06 33.82 0.65
TSS1 32.23 0.80 38.89 2.08
BT1 16.09 2.21 38.88 2.98
a Calculated from IC50 values in lg NFDPM/ml.
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Combes et al. (2012). Brieﬂy, Balb/c 3T3 clone A31 mouse ﬁbro-
blasts cells were maintained in tissue culture in Dulbecco’s Modi-
ﬁed Eagle’s Medium (DMEM) supplemented with 10% (v/v) foetal
calf serum (FCS), 4 mM L-glutamine and penicillin/streptomycin
(1% v/v). Cytotoxicity was expressed as a reduction in the uptake
of Neutral Red dye into the lysosomes of cells after a 48 h culture,
measured by absorbance at 540 nm. Serial dilutions of PM in DMSO
were made to determine concentration-dependent inhibition of
cell growth. Six wells were used for each concentration of test arti-
cle, vehicle or positive control; therefore testing was done with six
replicates. Two separate assays (experiments) were performed for
each test substance. For all experiments, the concentrations
(lg/ml) of the test article inducing a 50% inhibition in Neutral
Red Uptake (IC50) and the coefﬁcient of variance between values
for six replicates per concentration were estimated using validated
software (Phototox version 2).This protocol conforms to the guide-
lines issued by the National Institutes of Health (NIH) (NIH, 2001).
A higher IC50 value represents a lower cytotoxicity. IC50 values
were considered to be different when their variances did not
overlap.
The SAL mutagenicity test was performed as described by Com-
bes et al. (2012), using ﬁve Salmonella typhimurium strains: TA98,
TA100, TA102, TA1535 and TA1537, in the presence and absence
of S9. This experimental design used for the Ames test follows
CORESTA guidelines for testing tobacco and tobacco products.
One pre-incubation test and two plate incorporation tests were
performed. A further two plate incorporation tests using strains
TA98, TA100 and TA1537 in the presence of S9 were carried out
over the linear portion of the dose–response curve. The choice of
tester strains was consistent with previous observations on the
mutagenicity of tobacco smoke constituents and covered all of
the commonly-used strains, including those sensitive to heterocy-
clic amines, which are believed to contribute to the mutagenic ef-
fect of PMs and whose levels in smoke were expected to be
reduced by the changes made in tobacco design and composition.
All data were analysed using Dunnett’s test for signiﬁcant differ-
ences between solvent control plates and those treated with PM.
This method complied with OECD guideline 471 (OECD, 1997a)
and International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use
(ICH) guidelines (ICH, 1995, 1997). Results are presented as mean
revertants/lg NFDPM ± standard error of the mean (SEM) taken
from the results of four independent experiments for the plate
incorporation assays; and mean revertants/lg NFDPM ± standard
deviation (SD) of three replicates for each test concentration (ﬁve
replicates for vehicle control) for the single pre-incubation experi-
ment. Mutagenic potency was determined from the linear por-
tion(s) slopes of concentration–responses using linear regression
analysis. PMs were compared in terms of the slopes of their dose
responses. A generalised linear model was used to estimate slopes,
modelling the number of revertants using a Poisson distribution
with a log link function. Statistically signiﬁcant differences be-
tween slopes were identiﬁed by analysis of covariance (ANCOVA).
The IVMNT was performed as described by Combes et al.
(2012). Brieﬂy, four replicate V79 cell cultures in DMEM supple-
mented with 10% FCS and 0.52% penicillin/streptomycin, were
pulsed with test or control samples for 3 h followed by a 21 h
recovery, with and without S9, or for 24 h without S9. Cytochalasin
B, formulated in DMSO (0.1 ml), was added to all treatment ﬂasks
at time of treatment to give a ﬁnal concentration of 3 lg/ml. At
least 6 dose levels for each PM were scored for cytotoxicity and
for micronucleated binucleate cells (MnBn), on duplicate slides.
This method complied with OECD guideline 487 (OECD, 2010).
PMs were compared in terms of the slopes of their dose responses.
A generalised linear model was used to estimate slopes, modellingthe proportion of MnBn using a binomial distribution with a probit
link function. Statistically signiﬁcant differences between slopes
were identiﬁed by ANCOVA.
The MLA was performed as described by Combes et al. (2012),
using L5178Y thymidine kinase (tk) +/ cells cultured in supple-
mented Roswell Park Memorial Institute medium (RPMI).
In the main experiment 10 treatment concentrations were
tested with six vehicle control replicates and four treatment repli-
cates per concentration tested. Overall, there were two indepen-
dent experiments using a 3 h exposure with S9; and two
independent experiments using 3 and 24 h exposures without S9.
After a 2 day expression period, cells were grown for 8 days, and
then triﬂuoro-thymidine (TFT) resistant colonies were counted.
The method complied with OECD Guideline 476 (OECD, 1997b).
Data are plotted as the means of duplicate cultures within each
experiment. PMs were compared in terms of the slopes of their
dose responses. A generalised linear model was used to estimate
slopes, modelling log-transformed mutation frequency (MF) val-
ues. Statistically signiﬁcant differences between slopes were iden-
tiﬁed by ANCOVA. A test article was considered to be mutagenic in
this assay if: (a) the MF of any test concentration exceeded the sum
of the mean control mutant frequency plus GEF; and (b) the linear
trend test was positive.
3. Results
3.1. Neutral Red Uptake Assay
All samples were tested in the absence of S9 only, and were
cytotoxic, with relatively low intra-experimental variation, but
some inter-experimental variation in the results (Table 2). Consis-
tent with historical results, the IC50 values of the two reference
PMs were different, with the PM from ﬂue-cured blend (M4A)
being more cytotoxic than the PM from the US-style blend
(3R4F). CC1 was consistently the most cytotoxic sample, apart
from BT1 in one experiment.
The TSS1 and TSS6 PMs had higher IC50 values than their
respective controls (CC1 and CC6) in both repeat experiments, indi-
cating lower cytotoxicity. BT1 also differed from its control (CC1),
but the effect was not reproducible.
The IC50 values of PMs from cigarettes with 6 mg ISO tar yields
(TSS6 and CC6), were higher than those of PMs from cigarettes
with 1 mg tar yields (TSS1 and CC1), in two repeat experiments.
3.2. Salmonella typhimurium reverse mutation assay
All samples were mutagenic in the presence of S9, with activity
detected in tester strains TA98, TA100 and TA1537 (Figs. 1–5), but
were non-mutagenic, in tester strains TA102 and TA1535 (Table 5).
The mean numbers of revertants were calculated from the four val-
ues of the mean revertants/plate at each concentration, each mean
being derived from three replicate plates within each experiment.
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strains TA98 and TA100, but were non-mutagenic in the other tes-
ter strains in the absence of S9 (Table 5).
In the responsive strains, the degree of mutagenicity (rever-
tants/lg NFDPM) varied according to PM and tester strain. Consis-
tent with historical data, M4A gave lower mutagenicities than
3R4F in all experiments in TA98 and TA1537, although this was
only statistically signiﬁcant in TA1537 (Table 3).
Among the test cigarettes, there was no consistent difference
between CC1 and TSS1, or between CC6 and TSS6. In TA98,
TA100 and TA1537 the mutagenicities of BT1 were lower than
those of CC1 and TSS1 in all of the plate incorporation experiments
(Figs. 1–3). The reductions in mutagenicity were statistically signif-
icant in TA98 and TA1537 (Table 3). In strains TA98 and TA1537,
the pre-incubation mutagenicities of BT1 were lower than CC1
and TSS1 (Figs. 4 and 5). This was also observed with TA100, but
only at the non-linear part of the dose response (Fig. 6).Fig. 2. Bacterial mutagenicity of CC1 (continuous/triangles); TSS1 (dashes/dia-
monds) and BT1 (dashes and dots/squares) in TA1537 with S9 (means ± SEM of 4
independent plate incorporation experiments; error bars not visible are contained
within the data point; vehicle control mean (±SEM) count: 15.5 (0.83)).3.3. Mouse lymphoma assay
All PMs induced dose-related increases in cytotoxicity and MF,
in all treatment conditions (3 h ±S9 and 24 h S9; Table 4),
although some dose responses did not exceed the Global Evalua-
tion Factor (GEF). Consistent with historic data, M4A PM gave high-
er mutagenicity than 3R4F PM. This difference was statistically
signiﬁcant in four of the six experiments (Table 4).
Concentration-related increases in MF for each of the pairs of
control and treatment PM samples were obtained. Viabilities for
all of the concentrations of all of the PMs tested generally exceeded
70% in both experiments, irrespective of treatment parameters.
Table 4 presents induction of TFT-resistant colonies by refer-
ence, control and test PMs in the form of logMF/lg NFDPM. These
ﬁgures are from the linear part of the concentration–responses.
When the data for the two experiments in each treatment condi-
tion were combined, TSS1 and BT1 mutagenicities were lower than
that of CC1 PM (Fig. 7), and the reductions were statistically signif-
icant (Table 4). TSS6 was also less mutagenic than CC6 (Fig. 8)
when treatment was conducted for 3 h in the presence of S9. This
was statistically signiﬁcant in one experiment (Table 4). However,
this effect was not seen when S9 was omitted, or when exposure
was extended to 24 h in the absence of S9. In the latter case, the
response of TSS6 was also lower, but not signiﬁcantly so, possibly
due to high inter-experimental variation.Fig. 1. Bacterial mutagenicity of CC1 (continuous/triangles); TSS1 (dashes/dia-
monds) and BT1 (dots and dashes/squares) in TA98 with S9 (means ± SEM of 4
independent plate incorporation experiments; error bars not visible are contained
within the data point; vehicle control mean (±SEM) count: 29.9 (5.94)).
Fig. 3. Bacterial mutagenicity of CC1 (continuous/triangles); TSS1 (dashes/dia-
monds) and BT1 (dots and dashes/squares) in TA100 with S9 (mean ± SEM 4
independent plate incorporation experiments; error bars not visible are contained
within the data point; vehicle control mean (±SEM) count: 132.5 (2.78)).The dose responses included increases in the ratio of small to
large colonies, indicating deletions at the tk-locus (Cobb et al.,
1989). No large differences in the proportions of small colonies in-
duced were detected between each of the PM samples when tested
under the same conditions.3.4. In vitro micronucleus test
All PMs induced dose-related increases in cytotoxicity in the
three treatment conditions, and dose-related increases in the fre-
quency of micronucleated binucleate cells in two treatment condi-
tions (3 h ±S9) (Fig. 9a). Increases in the frequencies of MnBn cells
were also observed in the 20 h S9 treatment with all PMs, but
Fig. 4. Mutagenicity of CC1 (continuous/triangles); TSS1 (dashes/diamonds) and
BT1 (dots and dashes/squares) in TA98 with S9 (mean ± SD of three replicate plates
per dose in a pre-incubation assay (1 experiment); vehicle control mean (±SD)
count: 32.6 (9)).
Fig. 5. Mutagenicity of CC1 (continuous/triangles); TSS1 (dashes/diamonds) and
BT1 (dots and dashes/squares) in TA1537 with S9 (mean ± SD of three replicate
plates per dose in a pre-incubation assay (1 experiment); vehicle control mean
(±SD) count: 11 (1)).
Table 3
Mutagenicities of PMs in the Salmonella mutagenicity plate incorporation assay with
S9.
PM source Mean revertants/lg NFDPM (±SEM, n = 4 experiments)
TA98 + S9 TA100 + S9 TA1537 + S9
3R4F 1.8116 (0.0382) 0.6103 (0.0765) 0.3508 (0.0529)
M4A 1.4300 (0.0747) 0.4983 (0.1347) 0.2169 (0.0031)+
CC6 2.2385 (0.1761) 0.5464 (0.0341) 0.3398 (0.0578)
TSS6 1.9746 (0.2039) 0.7379 (0.0985) 0.2347 (0.0281)
CC1 2.7576 (0.5663) 0.7890 (0.1221) 0.3716 (0.0641)
TSS1 2.7677 (0.3883) 0.7932 (0.1559) 0.4186 (0.0432)
BT1 1.4744 (0.1284)* 0.5612 (0.1172) 0.2005 (0.0349)*
* Signiﬁcantly different from CC1 (TA98 p < 0.01; TA1537 p < 0.05) and TSS1
(TA98 and TA1537 p < 0.01).
+ Signiﬁcantly different (p < 0.05) from 3R4F.
Fig. 6. Mutagenicity of CC1 (continuous/triangles); TSS1 (dashed/diamonds) and
BT1 (dots and dashes/squares) in TA100 with S9 (mean ± SD of three replicate plates
per dose in a pre-incubation assay (1 experiment); vehicle control mean (±SD)
count: 116.8 (21.3)).
Table 4
Results from applying a generalised linear model to estimate slopes for induction of
TFT-resistant colonies by reference, control and test PMs.
PM source Slope (logMF/lg NFDPM)
3 h +S9 3 h S9 24 h S9
Expt. 1 Expt. 2 Expt. 1 Expt. 2 Expt. 1 Expt. 2
3R4F 0.0231* 0.0318 0.0340* 0.0311* 0.0455* 0.0584
M4A 0.0291 0.0332 0.0483 0.0439 0.0654 0.0706
CC6 0.0336 0.0215 0.0257 0.0311a 0.0414 0.0583
TSS6 0.0202^ 0.0254 0.0327 0.0275a 0.0367a 0.0530
CC1 Not linear 0.0217 0.0318 0.0418a 0.0424a 0.0522
TSS1 0.0194 0.0249a 0.0216+ 0.0301+ 0.0469a 0.0434
BT1 0.0379 0.0243 0.0155+ 0.0290+,a 0.0329a 0.0455
* Signiﬁcantly different from M4A (p < 0.05 3 h ±S9, p < 0.01 24 h S9).
+ Signiﬁcantly different from CC1 (p < 0.05).
^ Signiﬁcantly different from CC6 (p < 0.01).
 Signiﬁcantly different from BT1.
a GEF not exceeded.
Table 5
Results of Induction of micronuclei in cultured V79 cells by reference, control and test
PMs.
PM source logMnBn/lg NFDPM
3 h S9 3 h +S9 24 h S9
3R4F 0.00880* 0.00676* 0.00617*
M4A 0.01234 0.01180 0.01811
CC6 0.00791+ 0.00329 Not linear
TSS6 0.01184 0.00370 0.00523
CC1 0.00605# 0.00730# 0.01987#
TSS1 0.00572# 0.00636# 0.00419a
BT1 0.00943 0.01060 0.00675
* Signiﬁcantly different from M4A (3 h S9, p < 0.01; 3 h +S9 and 24 h S9,
p < 0.001).
+ Signiﬁcantly different from TSS6 (p < 0.001); TSS1 (TA98 p < 0.01, TA1537
p < 0.05).
# Signiﬁcantly different from BT1 (3 h S9, p < 0.01; 3 h +S9, p < 0.05 for CC1 and
p < 0.001 for TSS1; 24 h S9, p < 0.001).
a Negative slope excluded from statistical comparisons.
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was 3 h without S9, where up to 5-fold inductions of MnBn cells
were observed (Fig. 9b).Consistent with historical data, M4A PM induced more MnBn
cells than PM from 3R4F (Table 5). The differences were small,
but statistically signiﬁcant in all three treatments.
Fig. 7. Mutagenicity of CC1 (continuous/triangles); TSS1 (dashes/diamonds) and
BT1 (dots and dashes/squares) in the MLA; exposed for 3 h without S9 (means
(±SEM) from 2 independent experiments; vehicle control (67.44 ± 1.89) and GEF
combined = 193.44 mutants/106 surviving cells.
Fig. 8. Mutagenicity of CC6 (continuous/triangles) and TSS6 (dashes/squares) in the
MLA; 3 h treatment with S9 (mean ± SEM of 2 independent experiments; vehicle
control (78.75 ± 6.08) and GEF combined = 204.75 mutants/106 survivors).
Fig. 9a. Responses of CC1 (continuous/inverted triangles); TSS1 (dashes/diamonds)
and BT1 (dots and dashes/squares) in the IVMNT; 3 h incubation with S9
(mean ± SD of four replicate slides per dose; 1 experiment; vehicle control:
1.01 ± 0.46; % viabilities at top concentrations tested were: 49% (CC1); 26%
(TSS1); and 34% (BT1)).
Fig. 9b. Responses of CC1 (continuous/inverted triangles); TSS1 (dashes/diamonds)
and BT1 (dots and dashes/squares) in the IVMNT; 3 h incubation without S9
(mean ± SD of four replicate slides per dose; 1 experiment; vehicle control:
0.78 ± 0.16; % viabilities at top concentrations tested were: 43% (CC1); 55%
(TSS1); and 15% (BT1)).
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test PMs were also detected (Table 5). The slope of BT1 PM‘s dose
response was greater than those of CC1 and TSS1 in the 3 h treat-
ments, but less than CC1 in the 20 h treatment (Figs. 9a–9c). The
slope of TSS6 PM’s dose response was greater than that of CC6
PM in the 3 h S9 treatment (Fig. 10). Given the variability ob-
served within experiments, the shape of the dose responses, the
size of the possible differences and the levels of toxicity observed
at the higher doses, these statistical differences are not likely to
be biologically signiﬁcant.4. Discussion
The results are summarised qualitatively in Table 6.
These data broadly agree with observations made by previous
authors using PMs from a variety of tobaccos, ever since the origi-
nal observations of Kier et al. (1974). In summary, all PMs were
genotoxic in a variety of assays (Baker et al., 2004; Clive et al.,
1997; Cobb et al., 1989; COM, 2009; Combes et al., 2012; DeMarini
et al., 2008; DeMarini 2004; Guo et al., 2011; McAdam et al., 2011;
Mitchell et al., 1981; Richter et al., 2010; Rickert et al., 2011; Rick-
ert et al., 2007; Roemer et al., 2004, 2002; Sato et al., 1977). Cobb
et al. (1989) detected the induction of deletions at the tk locus,
which is compatible with our current observations and those made
earlier (Combes et al., 2012) that small colonies were induced by
all of the PM samples, with no discernible quantitative differences.
However, Putnam et al. (2002) did not ﬁnd a clear concentration-
related increase in cytotoxicity induced by PM in the NRU assay,
and Roemer et al. (2002) observed mutagenicity in Ames strains
TA98 and TA100 without S9. Also, on this occasion, extended treat-
ments were no more genotoxic than 3 h treatments in both the
MLA and the IVMNT, which contrasts with our previous observa-
tions with PMs obtained from a variety of cigarette types (Combes
et al., 2012) and published suggestions for including a 20 h treat-
ment regimen in protocols for the assay (Anon, 2004; Honma
et al., 1999b; Clements, 2000; Moore et al., 2007).
TSS has previously been shown to reduce the cytotoxicity and
genotoxicity of PM (McAdam et al., 2011), when included at more
than 30%. These authors found that, in the SAL assay, cigarettes
containing 60% TSS, with cellulose acetate ﬁlters gave signiﬁcantly
(p < 0.05) less mutagenicity than their respective controls when
tested in TA98, TA100 and TA1537 with S9, while those containing
30% TSS showed no statistical differences. Interestingly, in the
present experiments, the PMs from cigarettes containing 60% TSS
with a dual carbon ﬁlter were less genotoxic than their controls
in the IVMNT at all of the concentrations tested, whereas those
with 30% TSS were not signiﬁcantly different. In addition, no signif-
icant differences for any of the PMs that McAdam et al. (2011) used
in their study were detected in the MLA in our experiments, when
concentrations of the PMs were corrected for NFDPM content.
Our ﬁndings, that the SAL and IVMNT genotoxic potential of
TSS1 and TSS6 were not signiﬁcantly different from their respec-
tive controls (CC1 and CC6), are compatible with the data obtained
by McAdam et al. (2011), since the ECs in the present work only
contained 20% TSS, as opposed to those used earlier with higher
proportions of TSS. However, we also observed a reduction in
NRU cytotoxicity at a lower level of TSS than in McAdam et al.
(2011), and a small reduction in MLA genotoxicity without S9 mix.
Fig. 9c. Responses of CC1 (continuous/inverted triangles); TSS1 (dashes/diamonds) and BT1 (dots and dashes/squares) in the IVMNT; 24 h incubation without S9 (mean ± SD
of four replicate slides per dose; 1 experiment; vehicle control: 1.61 ± 0.6; % viabilities at top concentrations tested were: 47% (CC1); 36% (TSS1); and 28% (BT1)).
Fig. 10. Responses of CC6 (continuous/diamonds) and TSS6 (dashes/squares) in the
IVMNT; 3 h incubation without S9 (mean ± SD of four replicate slides per dose;
vehicle control 0.78 ± 0.16). % viabilities at top concentrations tested were: 40%
(CC6); and 46% (TSS6)).
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control cigarette, CC1. It is likely that the reduction of mutagenicity
was because BT1 contained blend-treated tobacco. BT tobacco did
not affect NRU cytotoxicity or IVMNT genotoxicity but a small
reduction in MLA genotoxicity was observed.
The reduction of bacterial mutagenicity, achieved with BT to-
bacco, as shown by the BT1 results, has been reported elsewhere
(Combes et al., 2012). These authors observed consistent and sta-
tistically signiﬁcant, reduced mutagenic potency (revertants/
lg NFDPM) in TA98 with S9, of PMs obtained from cigarettes made
with 80% BT tobacco, made at a different time, but using the same
process as employed to produce BT1 cigarettes used in this paper,
to reduce the level of toxicants in mainstream cigarette smoke
(MS). Moreover, the cigarettes containing BT tobacco, that were
shown by Combes et al. (2012) to exhibit reduced mutagenicity
compared with their controls, were constructed with the same
charcoal/resin ﬁlters. Interestingly, consistent and signiﬁcant
reductions in mutagenicity (seen with the ECs used in the earlier
experiments) were detected only in TA98, with the maximum de-
crease being 30% of the control. In the present study, the maximum
decrease was 87%, also in TA98, but with reductions in mutagenic-
ity also being detected in TA100 and TA1537. It is noteworthy that
the removal of protein from tobacco is reported to generate PMs
that, when tested with S9, exhibit mutagenicity that is reduced
by up to 80% in TA98 and by up to 50% in TA100 (Clapp et al.,1999).
The considerable reduction in protein nitrogen content, result-
ing from the use of BT tobacco, would be expected to decrease bac-
terial mutagenicity (Mizusaki et al., 1977), since it is a precursor ofnitrosamines and heterocyclic amines in tobacco smoke. Tobacco
treatment, should result in the generation (on smoking) of lower
levels of aromatic amines and heterocyclic amines (protein pyrol-
ysate products), which are considered to be the main cause of
mutagenicity in the Salmonella assay (Van Duuren et al., 1960;
DeMarini, 2004).
Moreover, the spectrum of activity seen in the Salmonella tester
strains is consistent with previous conclusions that the mutagenic-
ity of tobacco combustion products is primarily due to the genera-
tion of heterocyclic amines (DeMarini, 2004; Felton et al., 1995;
Sugimura et al., 2004; Mortelmans and Zeiger, 2000). In addition,
the spectrum of changes in mutagenicity seen with the tester
strains, being more pronounced in TA98 and TA1537 (both sensi-
tive to frame-shift mutagens), than in TA100, is consistent with
the removal from tobacco of heterocyclic amine precursors.
A different approach to investigate the effect of changing ciga-
rette composition on toxicity is to add various substances to tobac-
co and then to determine smoke chemistry and in vitro responses
(Gaworski et al., 2011). When three heterocyclic amines, 2-acetyl-
pyridine (AP), 2,3-diethylpyrazine (DEP) and 2,3,5,6-tetramethyl-
pyrazine (TMP) were separately added to cigarette tobacco, at
low, intermediate and high concentrations, and smoked, some
minor changes in smoke chemistry were detected with DEP only,
while there were no consistent effects on toxicity of either the
resulting gas–vapour or particulate phases of smoke, as measured
by in vitro cytotoxicity and bacterial mutagenicity (Coggins et al.,
2011a). While this would seem to contradict our data showing re-
duced mutagenicity with BT cigarettes, it should be noted that
none of these chemicals is considered to be mutagenic (EFSA,
2008; Müller and Rappert, 2010; John, 1982), and presumably
the smoking of tobacco containing them did not result in the gen-
eration of new, mutagenic heterocyclic amines. BT tobacco is also
characterised by having reduced levels of polyphenols, but these
were not tested by addition to tobacco (Gaworski et al., 2011).
However, it is noteworthy that, in another publication (Coggins
et al., 2011b), cytotoxicity was reduced by the highest inclusion
of triacetin into tobacco for both gas–vapour and particulate
phases of smoke, and mutagenicity was reduced by the middle
and high inclusion levels of triacetin into tobacco. A similar
smoke-dilution effect was also observed with glycerol and the
cytotoxicity data we obtained with TSS tobacco, which contains
high levels of glycerol. TSS cigarettes also contain high levels of cal-
cium carbonate, a substance that was unfortunately not tested by
Coggins and colleagues.
In conclusion, the data indicate that no consistent qualitative
differences were detected in the four in vitro tests, three of them
Table 6
Qualitative summary of in vitro data.
PM In vitro test
SAL IVMNT MLA NRU
S9 +S9 S9 +S9 S9 +S9 S9
TA102/TA1535/TA1537 TA98/TA100 TA102/TA1535 TA98/TA100/TA1537
3R4F  +  + + + + + +
M4A  +  + + + + + +
CC6  +  + + + + + +
TSS6  +  + + + + + +
CC1  +  + + + + + +
TSS1  +  + + + + + +
BT1  +  + + + + + +
: Inactive; +: active.
1540 R. Combes et al. / Toxicology in Vitro 27 (2013) 1533–1541genotoxicity assays, between PM samples obtained by individually
machine-smoking control and test cigarettes containing different
tobacco blends and ﬁlters, some of which contained tobacco
substituted sheet or BT tobacco to reduce levels of smoke toxicants
and their precursors. In addition, BT tobacco reduced mutagenicity
in the SAL, with strains TA98, TA100 and TA1537 in the presence of
S9. These observations are consistent with the hypothesis that
reducing tobacco protein content would reduce bacterial mutage-
nicity, without introducing any new genotoxic or cytotoxic hazard.
Further toxicity testing is warranted to investigate the effects of
the tobacco treatment in more detail, and to add to the data al-
ready obtained. Overall, the data show that the pre-incubation as-
say was more sensitive than plate-incorporation to the effects of
changing cigarette design. This result could not have been pre-
dicted at the start of the experiments and the main object of the
study was to see how changing tobacco design and composition
might affect overall genotoxicity proﬁles. Hence, it was felt impor-
tant to use a variety of Ames tester strains and protocols and other
genotoxicity assays. However, any further comparisons of the cig-
arettes used might well focus on use of the pre-incubation proto-
col. It is also noteworthy that preliminary short-term clinical
studies have demonstrated greater reductions in a range of bio-
markers of exposure to other potential toxicants, including acro-
lein and crotonaldehyde after smoking BT1 and TSS1 cigarettes,
when each is compared with the effects seen following smoking
their respective control CC1 cigarettes (Shepperd et al., 2009;
Shepperd et al., 2011).
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